Table of Contents - WOC 2012

FP-RET-TH 36 (7)
Continuous Monthly Anti-VEGF Therapy with Ranibizumab for Active
Polypoidal Choroidal Vasculopathy: Long Term Results
Kokame Gregg (1) , Lai James (1) , Yeung Ling (3) , Teramoto Kyla (1) , Wee Raymond
(1)
1. University of Hawaii School of Medicine, Retina Consultants of Hawaii
2. Retina Consultants of Hawaii
3. Chang Gung Hospital
Purpose: To evaluate the efficacy of monthly intravitreal injections of
ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and
active exudation or hemorrhage.
Methods: Prospective one year trial of monthly intravitreal ranibizumab (0.5
mg) injections for PCV in 13 eyes. Primary outcome measure was stabilization
of vision. Secondary outcome measures included ocular and systemic adverse
events and changes in central foveal thickness (CFT), subretinal hemorrhage,
and PCV on ICG angiography.
Results: Baseline findings included 9 eyes with subretinal fluid, 9 eyes with
subretinal hemorrhage, and 5 eyes with macular edema (CFT > 275 um).
11/13 eyes were treatment naive, 2/13 eyes received prior pDT. None of the
eyes lost > 15 letters of ETDRS vision. Subretinal hemorrhage resolved in
9/9 eyes (100%). Macular edema improved in 5/5 eyes. Polypoidal complexes
decreased in 5/13 eyes (38%).
Conclusions: Continuous monthly invtravitreal ranibizumab is well tolerated In
PCV. ranibizumab 0.5mg allows stabilization of vision, and reduction in macular
edema and subretinal hemorrhage. PCV regresses in only 38% of eyes, and
the branching vascular network persists in all eyes.
FP-RET-TH 36 (8)
Natural History and Treatment Outcomes of Polypoidal Choroidal
Vasculopathy (PCV) - A Five Year Study
Tan Colin (1,2,3) , Lim Louis (1) , Ngo Wei Kiong (1) , Gay Edwin (1) ,
Lim Tock Han (1,2)
1. National Healthcare Group Eye Institute
2. Department of Ophthalmology, Tan Tock Seng Hospital
3. Doheny Eye Institute, University of Southern California
Objective: Polypoidal choroidal vasculopathy (PCV) occurs more frequently in
Asians but there is limited information regarding its clinical course and
prognosis. We describe the epidemiology, natural history and outcomes of
PCV in Singapore.
Methods: A review of 102 consecutive patients (112 eyes) with PCV. Visual
outcomes were assessed up to 5 years.
Results: Serous-hemorrhagic presentations occurred in 82.9%. PCV were
predominantly located at the macula (86.0%). Good visual outcomes (visual
acuity [VA] ?20/40) were achieved in 41.1% at 5 years. Moderate visual loss
(loss of ? 3lines) occurred in 25% of patients. Patients who were untreated had
poorer visual outcomes (VA?20/200) (19.5% vs. 26.7%). Factors associated
with good visual outcome included good VA at start (p